Medical/Pharmaceuticals
Neoss Announces NeossONE™ - One Platform, Smart Prosthetics
NeossONE™ is a solution unique to the Neoss® Implant System - one prosthetic platform, across three implant ranges, including ALL implant diameters and abutments. Simply put, the same prosthetic components fit every implant.¹ HARROGATE, England, June 8, 2021 /PRNewswire/ -- ONE Prosthetic Platfo...
2021-06-08 18:15
4049
TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
LONGJUMEAU, France, June 8, 2021 /PRNewswire/ -- The French biotech TargEDys specialized in breakthrough microbiome-based solutions announces the publication of its study conducted in 230 overweight adults supplemented for 12 weeks, confirming the efficacy of the precision probioticHafnia alvei H...
2021-06-08 16:53
4227
Inspiring Women's Healthcare: Mindray Unveils Nuewa I9, a New OB/GYN Diagnostic Ultrasound System
SHENZHEN, China, June 8, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global
leading developer and provider of medical devices and solutions, has introduced
theNuewa I9
2021-06-08 15:37
9844
Copan strengthens its operations in the Americas with a millionaire investment
Copan announces a $78 million investment to expand its Puerto Rican production site. The project – partially financed byPuerto Rico's Government – will bring Copan production and distribution capacity closer to the American market, strengthening the company's presence in the US and the rest of th...
2021-06-08 14:00
3101
Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier
EPALINGES, Switzerland, June 8, 2021 /PRNewswire/ -- Onward Therapeutics (Onward) and Institut du Cancer de Montpellier (ICM) announced today the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by I...
2021-06-08 12:00
1738
Cytiva opens experience and learning lab in Singapore
* New lab will support Singapore government's Industry 4.0 agenda to build research, digital, innovation capability and talent development * Part of Cytiva's capacity expansion plan to meet the increasing demands for the biopharmaceuticals industry * Through this lab, Cytiva intends to run 7...
2021-06-08 10:00
2162
Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress
SAN FRANCISCO and SUZHOU, China, June 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-08 08:00
5325
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL
SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first...
2021-06-08 07:30
5379
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at t...
2021-06-08 07:21
12651
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care ...
2021-06-07 21:00
6448
Elekta's new strategy to focus on growth and access to radiation therapy
STOCKHOLM, June 7, 2021 /PRNewswire/ -- At Elekta's (EKTA-B.ST) Capital Markets Day, CEO,Gustaf Salford, and members from his executive management team introduced the company's mid-term strategy, called Access 2025. The strategy reflects the work the company will continue to do to pursue the visi...
2021-06-07 20:44
14029
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...
2021-06-07 20:00
7102
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a leading novel, dual-action, investigational COVID-19 oral pill Blinded blended mortality rates encourag...
2021-06-07 19:00
5252
Device Companies will Drive Surgery Automation to Increase Elective Procedures in Western Europe
Western European selective medical devices market for elective procedures is expected to reach$16.8 billion by 2023 at a CAGR of 29.2%, finds Frost & Sullivan SANTA CLARA, Calif., June 7, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Impact of COVID-19 on Elective Procedures in Wester...
2021-06-07 18:02
1818
Elekta and Philips deepen strategic partnership in precise and individualized oncology care
STOCKHOLM and AMSTERDAM, June 7, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) and Royal Philips (NYSE: PHG, AEX: PHIA) today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collab...
2021-06-07 16:02
6566
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021
SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...
2021-06-07 10:11
7088
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021
* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...
2021-06-07 10:10
6563
BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June
PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway. Worth three hundred thousand Euros, this prize is intended to reward a work with exceptional quality results and scientific relevance published in the last ten years in the bro...
2021-06-07 10:00
1742
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting
SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated toZhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001,...
2021-06-07 10:00
4392
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021
* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...
2021-06-07 09:53
6545
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6406
